<- Back to digest

Spine - 2026-10-23 - Journal Article

A Multicenter, Prospective, Single-arm Evaluation of Fusion Using a Rigorous 5-Factor Scale in Patients Undergoing 2- or 3-Level ACDF Supplemented with a Lineage-Committed Cellular Bone Matrix.

Usman Khalid M, Lavelle WF, Park P, Farhadi F

prospective cohortLOE IIn = 9512 months minimum; optional 24-month visit

Topics

spinebasic science
PMID: 42922078DOI: 10.1097/BRS.0000000000005913View on PubMed ->

Key Takeaway

Two- and three-level ACDF supplemented with ViviGen® cellular bone matrix achieved 73.0% overall fusion by a rigorous 5-factor scale, with 96% fusion on CT subset analysis at last follow-up.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This multicenter prospective study evaluated fusion rates and PROMs in 95 patients undergoing 2- or 3-level ACDF using interbody allograft supplemented with ViviGen® lineage-committed cellular bone matrix and anterior plating. A novel 5-factor fusion scale yielded 73.0% overall fusion versus 96% fusion by CT subset analysis, highlighting that scale stringency dramatically affects reported fusion rates. NDI, SF-12 PCS, and VAS all improved significantly (P<0.05); only translational motion ≤1.25 mm correlated with a clinical outcome (SF-12 PCS) on univariate analysis.

Key Limitation

The absence of a concurrent control group (autograft or alternative bone graft substitute) prevents any causal attribution of the observed fusion rates or PROM improvements to ViviGen® specifically.

Original Abstract

STUDY DESIGN

Prospective, observational multicenter clinical study.

OBJECTIVE

Evaluated cervical spine fusion using a 5-factor scale following multi-level ACDF. Secondary assessments included patient-reported outcome measures for pain and function and complications.

SUMMARY OF BACKGROUND DATA

Multi-level cervical degenerative spine disease causes pain, instability, and neurological impairment often requiring ACDF. Autologous bone poses harvesting challenges requiring consideration of alternatives such as allogenic and synthetic grafts. ViviGen® cellular bone matrix, containing osteoblasts, osteocytes and bone lining cells, exhibits osteogenic potential making it an option for bone fusion. Evaluating bone fusion from imaging remains a challenge, with no scientific consensus on assessment criteria.

METHODS

95 patients with 2- or 3-level ACDF enrolled between July 2016 and July 2018 in a multi-center, prospective study. Follow-up occurred at 6 weeks as well as 3, 6, 12, and optionally at 24 months. Standard ACDF approach was followed with interbody allograft spacer supplemented with ViviGen® cellular bone matrix and cervical plating. Statistical analysis included chi-square, t-test, and ANOVA tests.

RESULTS

5-factor successful fusion rates ranged from 63.8% to 77.6% for the C3-C4 to C6-C7 levels (73.0% overall). Single factor-based successful fusion ranged from 72.4% to 99.5% with bridging bone endplate to endplate present at 80.1% of levels at last follow-up based on independent assessment. CT analysis of a subset of patients identified 96% of levels fused. NDI, SF12 PCS, and VAS scores all improved significantly (P<0.05) during the follow-up period. Complications were limited and manageable. Only translational motion ≤1.25 mm correlated positively with a clinical outcome (SF12-PCS) on univariate analysis.

CONCLUSION

This study demonstrated favorable fusion outcomes after 2- or 3-level ACDF procedures using a lineage-committed cellular matrix using a rigorous 5-factor scale. Postoperative patient-reported outcomes showed significant improvement in pain and function. Consensus for fusion criteria assessing true bone graft efficacy is needed.